Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-1

C A Dinarello1

  • 1Department of Medicine, University of Colorado Health Science Center, Denver 80262, USA.

Cytokine & Growth Factor Reviews
|June 10, 1998
PubMed
Summary
This summary is machine-generated.

Interleukin-1 (IL-1) is a key inflammatory cytokine with narrow therapeutic benefits due to toxicity. Targeting IL-1 production or activity, particularly IL-1beta, offers promising clinical applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical, hematologic, and immunologic effects of interleukin-10 in humans.

Journal of clinical immunology·1996
Same author

Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha.

Arthritis and rheumatism·1996
Same author

Effect of endotoxin in IL-1 beta-deficient mice.

Journal of immunology (Baltimore, Md. : 1950)·1996
Same author

Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.

Experimental hematology·1996
Same author

Thermoregulation and the pathogenesis of fever.

Infectious disease clinics of North America·1996
Same author

Three distinct promoters direct transcription of different 5' untranslated regions of the human interleukin 1 type I receptor: a possible mechanism for control of translation.

Cytokine·1996
Same journal

Shared and context-specific mechanisms of T cell exhaustion in chronic viral infections and cancer: Transcriptional, metabolic, epigenetic, and therapeutic perspectives.

Cytokine & growth factor reviews·2026
Same journal

Temporal dynamics of type I interferon signaling in checkpoint inhibitor response and resistance.

Cytokine & growth factor reviews·2026
Same journal

The role of osteoprotegerin in colorectal cancer: Molecular interactions, mechanistic insights, and therapeutic implications.

Cytokine & growth factor reviews·2026
Same journal

Designing next-generation interleukin immunotherapy: A cytokine-guided framework for precision cancer therapy.

Cytokine & growth factor reviews·2026
Same journal

Fibroblast growth factor homologous factors in neural signaling: Molecular mechanisms and disease-relevant dysregulation.

Cytokine & growth factor reviews·2026
Same journal

Cytokine-mediated intrinsic and extrinsic regulation of anti-tumor adoptive T cell therapy.

Cytokine & growth factor reviews·2026
See all related articles

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Medicine

Background:

  • Interleukin-1 (IL-1) is a prototypic pro-inflammatory cytokine with two forms, IL-1alpha and IL-1beta, often acting with tumor necrosis factor (TNF).
  • While IL-1 enhances host defenses and acts as an immunoadjuvant, its narrow therapeutic window in humans limits clinical benefit due to toxicity.

Purpose of the Study:

  • To review current knowledge on Interleukin-1 (IL-1).
  • To highlight the regulatory mechanisms and therapeutic potential of targeting IL-1 activity.

Main Methods:

  • This review synthesizes existing research on IL-1.
  • It examines the synthesis, processing, secretion, and activity of IL-1, focusing on IL-1beta.
  • It also discusses natural inhibitors and regulatory mechanisms of IL-1 activity.

Related Experiment Videos

Main Results:

  • IL-1 significantly impacts nearly all cell types, often in conjunction with TNF.
  • The synthesis and activity of IL-1, especially IL-1beta, are under tight regulation.
  • Naturally occurring IL-1 receptor antagonist (IL-1Ra) and other regulatory mechanisms like soluble receptors and decoy receptors are crucial for down-regulating IL-1beta responses.

Conclusions:

  • Agents that reduce IL-1 production or activity hold significant potential for clinical applications.
  • The development of IL-1 inhibitors, such as IL-1Ra, is a key strategy for managing inflammatory conditions.
  • Understanding IL-1 regulation is vital for advancing therapeutic interventions in inflammatory diseases.